Non-contact ion transdermal drug delivery system and method

Abstract

The invention provides a non-contact ion transdermal drug delivery system and method, and belongs to the technical field of transdermal drug delivery. The system comprises an extraction unit and an ion regulation unit, the extraction unit comprises a high-voltage power supply, an extraction chamber and an electrode; the electrode is connected with a high-voltage power supply and is vertically arranged in the extraction chamber; the extraction chamber comprises an extraction area, a conical connection area and a micropore area in which a micropore channel is formed, which are sequentially distributed from top to bottom; the ion adjusting unit comprises a stepped electric field chamber, an ion adjusting module and a guide power supply; and the ion adjusting module comprises at least two groups of coaxial annular electrodes which are distributed at intervals up and down. The method comprises the following steps: placing a medicine and a solvent in an extraction chamber, generating an electrofluid under the action of direct-current high voltage, extracting medicine active molecules and converting the medicine active molecules into medicine active ions; and the active ions enter the stepped electric field chamber to generate drug active ion clusters, and permeate into a drug-administered area. The invention develops a transdermal drug delivery system and a transdermal drug delivery method which have the advantages of no contact, no exogenous pollution, in-situ extraction, high utilization rate and good penetrability.

Description

Technical Field

[0001] The invention belongs to the technical field of transdermal drug delivery, and in particular relates to a non-contact ion transdermal drug delivery system and method. Background Art

[0002] Transdermal drug delivery is an important drug delivery route that can provide sustained and stable drug release, avoid first-pass effect, and improve drug bioavailability. Transdermal drug delivery is widely used in the treatment of chronic diseases, pain control, and topical applications. At present, research on transdermal drug delivery mainly focuses on optimizing transdermal absorption systems, improving drug penetration, and improving skin biocompatibility. However, this field still faces some challenges; for example, how to effectively break through the natural barrier of the skin under non-invasive conditions to achieve efficient drug delivery.

[0003] Ion electroosmosis is a physical process in which ions diffuse in a medium under the drive of electric field force. External electric field force can be used to enhance the permeability of drugs through the membrane into the subcutaneous tissue, thereby achieving efficient drug delivery.

[0004] However, the existing ion permeation drug delivery technology still has many limitations in practical applications. For example, it relies on high current intensity to drive the drug through the skin, which may lead to adverse reactions such as skin polarization, erythema or burns, and the drug utilization rate is low, the permeability is poor, and the transdermal efficiency needs to be improved. In addition, traditional ion permeation technology usually requires the drug itself to be in ionic form and needs to be in contact with the skin for a long time, which further limits its scope of application. Summary of the invention

[0005] In view of this, an object of the present invention is to provide a non-contact ion transdermal drug delivery system and method, aiming to solve at least one technical problem in the background technology.

[0006] The present invention is achieved in that: A first aspect of the present invention provides a non-contact ion transdermal drug delivery system, which includes an extraction unit and an ion adjustment unit; The extraction unit comprises: A high voltage power supply for providing the electric fluid required to extract the active molecules of the drug; The extraction chamber is used to separate the active molecules in the drug and convert the active molecules of the drug into active ions of the drug at the front end of the microporous area of ​​the extraction chamber; An electrode, which is electrically connected to the high voltage power supply and vertically arranged inside the extraction chamber; The ion adjustment unit comprises: A stepped electric field chamber, which is located below the extraction chamber and connected to the extraction chamber; An ion regulating module is built into the stepped electric field chamber and forms a stepped electric field, and is used to form drug-active ions into drug-active ion clusters. The ion regulating module is in non-contact with the skin of the drug-administered area; A pilot power source, which supplies power to the ion adjustment module; Wherein, the ion adjustment module comprises at least two groups of coaxial annular electrodes spaced apart from each other; Preferably, the extraction chamber comprises an extraction zone, a microporous zone with a microporous channel therein, and a conical connection zone connecting the extraction zone and the microporous zone, and the electrode is inserted from the extraction zone and penetrates into the microporous zone; the electrode is electrically connected to a high voltage power supply; the pore size of the microporous channel is 5 μm to 500 μm, the length of the microporous channel is 1 mm to 30 mm, and the shape is cylindrical or truncated conical; Preferably, the extraction zone is externally provided with a heating element and a vibrating device; The heating element heats the interior of the extraction zone; The vibration device provides mechanical vibration inside the extraction area.

[0007] Preferably, each group of annular electrodes is electrically connected to a guiding power supply, which outputs DC voltages of different magnitudes to each group of annular electrodes. The DC voltage increases from top to bottom to form a stepped electric field, and the DC voltage ranges from 10V to 50V or -50V to -10V.

[0008] Preferably, the annular electrode is in the stepped electric field chamber, with a through hole formed in the middle, and the aperture of the through hole gradually increases from top to bottom.

[0009] Preferably, the high-voltage power supply outputs a continuous DC voltage or a discontinuous DC voltage to generate an electric current; the DC voltage cycle output by the high-voltage power supply has a minimum value of 1 μs, a duty cycle of 1% to 100%, and a magnitude of -5kV to +5kV.

[0010] Preferably, the material of the electrode is selected from at least one of platinum, gold, graphite, glassy carbon, titanium, stainless steel, silicon nitride, titanium nitride, and ceramics; The material of the extraction chamber is selected from at least one of polytetrafluoroethylene, polyetheretherketone, fluororubber, polyphenylene sulfide, polyethylene and glass.

[0011] The second aspect of the present invention provides a non-contact ion transdermal drug delivery method, which uses the above-mentioned non-contact ion transdermal drug delivery system; the transdermal drug delivery system is placed above the drug delivery area; the transdermal drug delivery method comprises the following steps: providing drugs and solvents; placing the drug and the solvent in an extraction chamber, with the solvent submerging the drug; The high-voltage power supply applies a DC voltage to the solvent in the extraction chamber through electrodes to generate an electric fluid, which passes through the microscopic gaps in the drug to extract the active molecules in the drug; after flowing through the microporous channels, the solvent is atomized and the active molecules of the drug are converted into active ions of the drug; The drug-active ions enter the stepped electric field chamber, and the ion adjustment module outputs multiple groups of stepped DC voltages of different sizes, so that a stepped electric field is formed around the drug-active ions, generating drug-active ion clusters; The drug-active ion clusters penetrate into the skin of the area to which they are administered.

[0012] Preferably, the drug is in the form of solid, liquid or paste; the drug source is Chinese medicinal materials or finished drugs in different dosage forms; The solvent is selected from at least one of water, ethanol or propylene glycol.

[0013] Preferably, the distance between the ion regulating module and the skin of the drug administration area is 1 cm to 8 cm.

[0014] Compared with the prior art, the present invention has the following beneficial effects: 1. The present invention uses high-voltage current fluid to extract drug active molecules in situ + step electric field to generate drug active ion clusters, so that the effective ingredients in the drug are efficiently precipitated and can penetrate into the drug administration area in a non-contact manner, avoiding damage to human skin, and developing a non-contact, exogenous pollution-free, in-situ extraction, higher utilization rate and better penetration transdermal drug delivery device and method.

[0015] 2. The present invention provides DC high voltage to drugs and solvents through a high-voltage power supply to generate an electric fluid, which passes through the gaps between molecules or tissues, assisted by heating and vibration, to efficiently extract the active molecules in the drug; then the electric fluid containing the active drug molecules flows through the microporous channel and is atomized to remove the solvent, and the active drug molecules are converted into ionic states; using this soft ionization technology, the neutral molecules in the active components of the drug can be converted into ions without any damage to the active molecules, thereby achieving transdermal administration of the active drug components after ionization, which has a certain universality.

[0016] 3. The present invention sets a stepped electric field chamber below the extraction chamber, and forms a stepped electric field around the drug-active ions by applying a stepped DC voltage to a plurality of groups of annular electrodes, generating drug-active ion clusters. The stepped electric field is used to control the speed and size of the drug-active ion clusters and improve their transdermal permeability. The drug-active ions can effectively penetrate the skin and enter the blood circulation system to achieve the purpose of drug administration.

[0017] 4. The method of the present invention does not use any harmful reagents and can extract drugs in situ without complicated pretreatment or exogenous reagent assistance, ensuring that the active molecules of the drugs maintain their natural active state during the extraction process. This in situ extraction method not only retains the active ingredients of the drugs to the maximum extent, but also significantly improves the utilization rate of the drugs, providing a more efficient and safer solution for transdermal drug delivery. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 It is a schematic diagram of the structure of the ion transdermal drug delivery system of the present invention; Figure 2 It is a schematic structural diagram of a simulation experimental device for an ion transdermal drug delivery system according to Example 2 of the present invention; Figure 3 The primary mass spectrum of the active ions extracted from Rhizoma Coptidis in Example 2 of the present invention; Figure 4 The secondary mass spectrum of the active ions extracted from Rhizoma Coptidis in Example 2 of the present invention is shown in FIG. Figure 5 The UV absorption diagram of the physiological saline in the diffusion cell before and after the transdermal experiment in Example 2; Figure 6 This is a comparison chart of the mass spectrometry signal intensity of berberine after different treatments in Example 3; Figure 7 is a comparison chart of mass spectrometry signal intensities of berberine after different treatments in Example 4; Figure 8 is a graph showing the change of current magnitude over time in Example 4; Fig. 9 The UV absorption diagram of the physiological saline in the diffusion cell before and after the transdermal experiment in Example 5; Fig.10 The UV absorption diagram of the physiological saline in the diffusion cell before and after the transdermal experiment in Example 6; Fig.11 Graphs showing the ultraviolet absorption of the physiological saline in the diffusion cell before and after the transdermal experiment in Example 7.

[0019] Illustrations: 1-extraction area, 2-heating element, 3-electrode, 4-vibration device, 5-conical connection area, 6-micropore area, 7-step electric field chamber, 8-ion adjustment module, 9-through hole, 10-high voltage power supply, 11-auxiliary power supply, 12-guide power supply, 13-diffusion cell, 14-magnetic stirring bar, 15-artificial skin, 16-clamp, 17-cover. DETAILED DESCRIPTION

[0020] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific implementation cases described herein are only used to explain the present invention and are not used to limit the present invention.

[0021] Example 1 like Figure 1 As shown, a non-contact ion transdermal drug delivery system comprises an extraction unit and an ion regulating unit; The extraction unit includes: a high-voltage power supply 10, which is used to provide the electric fluid required for extracting the active molecules of the drug; an extraction chamber, which is used to separate the active molecules in the drug; an electrode 3, which is electrically connected to the high-voltage power supply 10 and is vertically arranged inside the extraction chamber; The ion adjustment unit includes: a stepped electric field chamber 7, which is located below the extraction chamber and connected to the extraction chamber; an ion adjustment module 8, which is built into the stepped electric field chamber 7 and forms a stepped electric field for forming drug-active ions into drug-active ion clusters; and a guide power supply 12, which supplies power to the ion adjustment module 8.

[0022] The extraction chamber includes an extraction area 1 with an external heating element 2 and a vibration device 4, a microporous area 6 with a microporous channel, and a conical connection area 5 connecting the extraction area 1 and the microporous area 6; the pore size of the microporous channel is 5μm~500μm, the length of the microporous channel is 1mm~30mm, and the shape is cylindrical or truncated cone; the extraction chamber is made of highly chemically resistant inert materials, such as polytetrafluoroethylene, polyetheretherketone, fluororubber, polyphenylene sulfide, polyethylene, glass and other materials, which can prevent contamination of the drug delivery system. The electrode 3 is vertically arranged inside the extraction chamber, inserted from the extraction area 1 and penetrates into the microporous area 6; the electrode 3 is electrically connected to the high-voltage power supply 10; in order to ensure that no chemical reaction occurs with the extracted drugs, solvents, etc. under power-on conditions, the material of the electrode 3 is adjusted according to actual needs, such as platinum, gold, graphite, glassy carbon, titanium, stainless steel, silicon nitride, titanium nitride, ceramics, etc.

[0023] The high-voltage power supply 10 outputs a continuous DC voltage or a discontinuous DC voltage to generate an electric fluid. To ensure efficient in-situ extraction of the drug, the DC voltage cycle output by the high-voltage power supply has a minimum value of 1μs, a duty cycle of 1% to 100%, and a magnitude of -5kV to +5kV. The electric fluid passes through the microscopic gaps in the drug through the electrode 3, and with the assistance of the heating element 2 and the vibration device 4, the active molecules in the drug are effectively separated.

[0024] In the specific implementation, the heating element 2 and the vibration device 4 are electrically connected to the auxiliary power supply 11 respectively. The heating element 2 heats the inside of the extraction area 1, and its controllable temperature range is room temperature RT~100℃. The specific temperature setting can be adjusted according to the medicine and the solvent; the vibration device 4 provides high-frequency mechanical vibration for the inside of the extraction area 1, and the vibration device 4 can adopt a mechanical vibration device or an ultrasonic vibration device; the present invention applies energy to the extraction area 1 through the heating element 2 and the vibration device 4, and the drug sample in the extraction area 1 is subjected to the dual effects of heat energy and high-frequency vibration, wherein the heat energy increases the temperature and enhances the molecular thermal motion, while the high-frequency vibration promotes the molecular motion and forms a cavitation effect. The synergistic effect of the two not only accelerates the extraction process, but also improves the extraction rate and purity of the target component, making the entire extraction process more efficient and environmentally friendly.

[0025] The stepped electric field chamber 7 has an ion adjustment module 8 built in. The ion adjustment module 8 includes at least two groups of coaxial annular electrodes spaced apart from each other. Each group of annular electrodes is electrically connected to a guide power source 12. The guide power source 12 applies a positive voltage or a negative voltage to each group of annular electrodes. Each group of annular electrodes outputs a DC voltage of different magnitudes. The DC voltage range is -50V to +50V, specifically 10V to 50V or -50V to -10V. From top to bottom, each group of annular electrodes outputs an increasing DC voltage value to form a stepped electric field. The positive and negative voltages are set according to the characteristics of the active ions in the drug. If the target component to be delivered is a positive ion, a positive voltage is applied, otherwise a negative voltage is applied. When a negative voltage is applied, the increasing DC voltage value means that the absolute value of the output DC voltage increases. A through hole 9 is formed in the middle of the annular electrode, and the aperture of the through hole 9 gradually increases from top to bottom.

[0026] In a specific implementation, the active molecules of the drug are dissolved in the solvent and converted into drug-active ions in the extraction chamber, and then enter the step electric field chamber 7, and move downward along the through hole 9. As the ion adjustment module 8 outputs multiple groups of stepped DC voltages of different sizes inside the step electric field chamber 7, a step electric field is formed around the drug-active ions. The step electric field is used to focus the drug-active ions to form drug-active ion clusters. The step electric field controls the speed and size of the drug-active ion clusters and improves their transdermal permeability to achieve the purpose of drug administration.

[0027] In the specific implementation, the drug and the solvent are placed in the extraction chamber, and the solvent immerses the drug. The drug forms include solid, liquid, and paste. The source of the drug is mainly Chinese herbal medicine or finished medicines of different dosage forms, which can be placed in the extraction chamber for administration; in order to ensure the safety of the skin at the medication site, it is preferred to select harmless agents to the human body as solvents, such as water, ethanol, and propylene glycol.

[0028] Example 2 In this embodiment, a transdermal experimental device is built based on the non-contact ion transdermal drug delivery system shown in Example 1 to conduct a simulation experiment. Figure 2 shown.

[0029] The artificial skin 15 is placed below the stepped electric field chamber 7, and the artificial skin 15 is 1 cm to 8 cm away from the end of the stepped electric field chamber 7 (5 cm in this embodiment). A diffusion pool 13 is set below the artificial skin 15, and the diffusion pool 13 has a built-in magnetic stirrer 14. The artificial skin 15 is fixed to the diffusion pool 13 by a cover 17 and a horseshoe-shaped clamp 16 set on the outer edge. The diffusion pool 13 is filled with physiological saline to simulate human subcutaneous tissue fluid, and the diffusion pool 13 is placed in a constant temperature device, and the temperature in the diffusion pool 13 is set to 36°C; the artificial skin completely covers the diffusion pool 13.

[0030] In this embodiment, the electrode 3 is a graphite electrode, the pore size of the microporous channel is set to 200 μm, and the length of the microporous channel is set to 15 mm; the ion adjustment module 8 uses 6 groups of annular electrodes; the drug uses the Chinese medicinal material Coptis chinensis, and the solvent uses ethanol. The main active ingredient in Coptis chinensis is berberine, which can be used to treat bacterially infected ulcers and dengue fever.

[0031] The non-contact ion transdermal drug delivery method in this embodiment includes the following steps: S1. Mix the coptis root powder and ethanol and heat to 45°C to dissolve the berberine in the coptis root, then add an equal amount of ultrapure water to form a coptis root solution with a concentration of 100 ppm, and place the solution in an extraction chamber; S2, start the high-voltage power supply, apply a DC voltage to the coptis solution through the electrode to generate an electrofluid, the DC voltage parameters include: the DC voltage is +5kV, the period is 2μs, and the duty cycle is 50%; start the heating element and the vibration device at the same time, the electrofluid passes through the microscopic gaps of the coptis, and the active molecules (such as berberine) are extracted with the assistance of the heating element and the vibration device; the electrofluid containing the active molecules moves downward through the microporous area, and after flowing through the microporous channel, it is atomized to remove the solvent, and the active molecules are converted into active ions; the active ions generated in this step are detected by a mass spectrometer, and the primary mass spectrum and the secondary mass spectrum are shown as follows: Figure 3 and Figure 4 As shown; S3, starting the guide power supply, outputting different DC voltages to each group of annular electrodes, the range of which is +10V to +50V, with the voltage value increasing from top to bottom, and the voltage difference between two adjacent annular electrodes being substantially the same, thereby forming a step electric field around the active ions of the drug, and utilizing the step electric field to focus the active ions to form active ion clusters; S4. Active ion clusters penetrate into the artificial skin and enter the diffusion pool below.

[0032] Figure 5 The UV absorption diagram of the physiological saline in the diffusion cell before and after the transdermal experiment (the experimental time is 120 minutes) is shown in Figure 1. Figure 5It can be seen that after the transdermal experiment, the berberine of the drug effectively penetrated through the artificial skin into the physiological saline.

[0033] Example 3 On the basis of Example 2, the heating and vibration operations in step S2 were adjusted to set a comparison group. The other steps were the same, and the specific grouping was as follows: Group A is without heating and vibration; Group B was heating only and without vibration; Group C was no heating and only vibration; Group D is heated and vibrated, i.e., Example 2; The mass spectrometry signal intensity of berberine in the saline solution in the diffusion cell under the above different treatment conditions was tested. Figure 6 As shown, it can be seen that group D>group C>group B>group A; from this, it can be seen that the berberine content in the normal saline is higher after heating and vibration, indicating that heating and vibration promote the precipitation and transdermal permeability of berberine.

[0034] Example 4 The distribution of the electric field and the through-holes in step S3 is adjusted on the basis of Example 2, and the other steps are the same, and the specific grouping is as follows: Group A was without step electric field; Group B applied a low voltage electric field, that is, outputting +10V voltage to each group of annular electrodes; Group C applied a high voltage electric field, that is, +50V voltage was output to each group of annular electrodes; Group D is a step electric field with decreasing voltage, that is, a DC voltage of +10V to +50V is output to each group of annular electrodes, and the voltage value decreases from top to bottom; Group E is a step electric field with increasing voltage applied, and the aperture of the through hole 9 in each group of annular electrodes remains unchanged, and its aperture is the same as the aperture of the lowest through hole 9 in Example 2; Group F is a step electric field with increasing voltage applied, and the aperture of the through hole 9 in each group of annular electrodes gradually decreases from top to bottom; Group G is a step electric field with increasing voltage applied, and at the same time, the aperture of the through hole 9 in each group of annular electrodes gradually increases from top to bottom, that is, Example 2.

[0035] The mass spectrometry signal intensity of berberine in the physiological saline in each group of diffusion cells was tested and compared with that before the transdermal experiment. Figure 7 As shown. Figure 7It can be seen that the comparison results of the mass spectrometry signal intensity of berberine under different electric field forms are: Group G>Group D>Group C>Group B>Group A. The berberine content in the saline was the highest after applying a step electric field with increasing voltage, and the berberine content in the saline decreased in turn after applying a step electric field with decreasing voltage, a high voltage electric field, a low power electric field, and a step electric field without voltage. This shows that the step electric field with increasing voltage increases the transdermal permeability of the drug and achieves the purpose of efficient drug delivery. In addition, Figure 7 It can be seen that under different through-hole aperture distributions, the comparison results of the mass spectrometry signal intensity of berberine are: Group G>Group F>Group E, and the effect of through-hole aperture distribution on the transdermal permeability of the drug is: the through-holes gradually become larger, the distance between individual active ion clusters gradually becomes larger, the distribution of active ion clusters gradually becomes uniform, making it difficult for the active ion clusters to condense and increase, and the drug microdroplets will spontaneously evaporate the residual solvent due to the surface effect, making the active ion clusters further smaller. As the aperture gradually increases, the residual solvent is removed faster, the active ion clusters become smaller and smaller, and then the transdermal permeability is higher when they reach the artificial skin.

[0036] In the case of applying a step electric field, the change of the current of drug ions over time during drug administration is detected, such as Figure 8 As shown by Figure 8 It can be seen that the ion current of the transdermal drug delivery system during its operation hardly changes over time, and its value does not exceed 0.15 microamperes. It is safe and reliable and will not cause harm to human skin.

[0037] Example 5 The drug in step S1 is modified based on Example 2.

[0038] The non-contact ion transdermal drug delivery method in this embodiment includes the following steps: S1. Mix nicotinamide and ethanol water (ethanol: water = 1:1 by volume) and heat to 45° C. to prepare a nicotinamide solution with a concentration of 100 ppm, and place the solution in an extraction chamber; S2, start the high-voltage power supply, apply a DC voltage to the nicotinamide solution through the electrode to generate an electric fluid, the DC voltage parameters include: the DC voltage is +5kV, the period is 2μs, and the duty cycle is 50%; start the heating element and the vibration device at the same time, the electric fluid containing the active ingredient (nicotinamide) moves downward through the microporous area, and after flowing through the microporous channel, the solvent is atomized and removed, and the active ingredient is converted into active ions; S3, starting the guide power supply to output different magnitudes of step DC voltage to each group of annular electrodes, the range of which is +10V to +50V, so as to form a step electric field around the active ions of the drug, and to use the step electric field to focus the active ions to form active ion clusters; S4. Active ion clusters penetrate into the artificial skin and enter the diffusion pool below.

[0039] Fig. 9 is the ultraviolet absorption diagram of the physiological saline in the diffusion cell before and after the transdermal experiment in this embodiment (the experimental time is 10 minutes), Fig. 9 It can be seen that after the transdermal experiment, niacinamide effectively penetrated the artificial skin into the physiological saline.

[0040] Example 6 In this example, hyaluronic acid is used to replace the niacinamide in Example 5, and other steps and conditions are consistent with Example 5.

[0041] Fig.10 is the ultraviolet absorption diagram of the physiological saline in the diffusion cell before and after the transdermal experiment in this embodiment (the experimental time is 10 minutes), Fig.10 It can be seen that after the transdermal experiment, hyaluronic acid effectively penetrated the artificial skin into the physiological saline.

[0042] Example 7 In this example, collagen was used to replace the nicotinamide in Example 5, and other steps and conditions were the same as those in Example 5.

[0043] Fig.11 is the ultraviolet absorption diagram of the physiological saline in the diffusion cell before and after the transdermal experiment in this embodiment (the experimental time is 10 minutes), Fig.11 It can be seen that after the transdermal experiment, collagen effectively penetrated the artificial skin into the physiological saline.

[0044] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A non-contact ion transdermal drug delivery system, characterized in that: The transdermal drug delivery system comprises an extraction unit and an ion adjustment unit; The extraction unit comprises: A high voltage power supply for providing the electric fluid required to extract the active molecules of the drug; An extraction chamber is used to separate active molecules from the drug and convert the drug active molecules into drug active ions at the front end of the extraction chamber; An electrode, which is electrically connected to the high voltage power supply and vertically arranged inside the extraction chamber; The ion adjustment unit comprises: A stepped electric field chamber, which is located below the extraction chamber and connected to the extraction chamber; An ion regulating module is built into the stepped electric field chamber and forms a stepped electric field, and is used to form drug-active ions into drug-active ion clusters, and the ion regulating module is in non-contact with the skin of the drug-administered area; A pilot power source, which supplies power to the ion adjustment module; Wherein, the ion adjustment module comprises at least two groups of coaxial annular electrodes spaced apart from each other; The extraction chamber comprises an extraction zone, a microporous zone with microporous channels therein, and a conical connection zone connecting the extraction zone and the microporous zone. The electrode is inserted from the extraction zone and penetrates into the microporous zone; the electrode is electrically connected to a high voltage power supply.

2. A non-contact ion transdermal drug delivery system according to claim 1, characterized in that: The pore size of the microporous channel is 5 μm to 500 μm, the length of the microporous channel is 1 mm to 30 mm, and the shape is cylindrical or truncated conical.

3. A non-contact ion transdermal drug delivery system according to claim 1, characterized in that: The extraction zone is externally provided with a heating element and a vibrating device; The heating element heats the interior of the extraction zone; The vibration device provides mechanical vibration inside the extraction area.

4. A non-contact ion transdermal drug delivery system according to claim 1, characterized in that: Each group of annular electrodes is connected to a guiding power supply, which outputs DC voltages of different magnitudes to each group of annular electrodes. The DC voltage increases from top to bottom to form a step electric field. The DC voltage range is 10V to 50V or -50V to -10V.

5. A non-contact ion transdermal drug delivery system according to claim 1, characterized in that: The annular electrode is in the stepped electric field chamber, with a through hole formed in the middle, and the aperture of the through hole increases gradually from top to bottom.

6. The non-contact ion transdermal drug delivery system according to claim 1, characterized in that: The high-voltage power supply outputs a continuous DC voltage or a discontinuous DC voltage; the DC voltage cycle output by the high-voltage power supply has a minimum value of 1μs, a duty cycle of 1% to 100%, and a magnitude of -5kV to +5kV.

7. The non-contact ion transdermal drug delivery system according to claim 1, characterized in that: The material of the electrode is selected from at least one of platinum, gold, graphite, glassy carbon, titanium, stainless steel, silicon nitride, titanium nitride, and ceramics; The material of the extraction chamber is selected from at least one of polytetrafluoroethylene, polyetheretherketone, fluororubber, polyphenylene sulfide, polyethylene and glass.

8. A non-contact ion transdermal drug delivery method, characterized in that: The transdermal drug delivery method adopts a non-contact ion transdermal drug delivery system according to any one of claims 1 to 7; the transdermal drug delivery system is placed above the drug delivery area; The transdermal administration method comprises the following steps: providing drugs and solvents; placing the drug and the solvent in an extraction chamber, with the solvent submerging the drug; The high-voltage power supply applies a DC voltage to the solvent in the extraction chamber through electrodes to generate an electric fluid, which passes through the microscopic gaps in the drug to extract the active molecules of the drug; after flowing through the microporous channels, the solvent is atomized and the active molecules of the drug are converted into active ions of the drug; The drug-active ions enter the stepped electric field chamber, and the ion adjustment module outputs multiple groups of stepped DC voltages of different sizes, so that a stepped electric field is formed around the drug-active ions, generating drug-active ion clusters; The drug-active ion clusters penetrate into the skin of the area to which they are administered.

9. A non-contact ion transdermal drug delivery method according to claim 8, characterized in that: The drug is in the form of solid, liquid or paste; the drug source is medicinal materials or finished drugs in different dosage forms; The solvent is selected from at least one of water, ethanol or propylene glycol.

10. The non-contact ion transdermal drug delivery method according to claim 8, characterized in that: The distance between the ion regulating module and the skin of the drug-administered area is 1 cm to 8 cm.

Images